A Single Arm, Open-label Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of NM-IL-12 (RHUIL 12) in Patients with Cutaneous T Cell Lymphoma (CTCL) Undergoing Low Dose Total Skin Electron Beam Therapy (TSEBT)
A study for patients with Cutaneous T Cell Lymphoma (CTCL) using study drug NM-IL-12
Sponsor: Neumedicines
Enrolling: Male and Female Patients
IRB Number: AAAQ5717
U.S. Govt. ID: NCT02542124
Contact: Ryan Shelton: 212-304-5485 / rs3323@cumc.columbia.edu
Additional Study Information: This is a research study to test the effectiveness of NM-IL-12 an experimental drug, in combination with low dose Total Skin Electron Beam Therapy (TSEBT) for treatment of Cutaneous T Cell Lymphoma. The study will enroll 10 subjects age 18 years and older.Treatment will consist of 3 weeks of TSEBT, and up to 27 weeks of NM-IL-12 treatment starting from day 2 of TSEBT. A 4 week follow-up period will take place following the last treatment of NM-IL-12. Measurements of general safety and toxicity will be used to determine the effectiveness of the drug.
This study is closed
Larisa Geskin, MD
Do You Qualify?
Have you been diagnosed with lymphoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Ryan Shelton